Drug recall: Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC…

Class II FDA enforcement event 99552. Recall start date: 4 Aug 2026. Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Failed Dissolution Specifications

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Novartis Pharmaceuticals Corporation started this drug recall on 4 Aug 2026. The firm address in the FDA record is in East Hanover, NJ. FDA put the recall in Class II. FDA event 99552 has 1 product record. The first FDA enforcement report date is 19 Aug 2026. The record gives the status Ongoing.

FDA enforcement report The 1 product record

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.
FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on 1 Oct 2026. openFDA export of 28 Sep 2026.

Distribution

In the words of FDA.

US Nationwide

Recalling firm

Novartis Pharmaceuticals Corporation, East Hanover, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 99552: product records
Recall number	Product	Quantity	Class	Status	Report date
D-0746-2026	Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34		Class II	Ongoing	19 Aug 2026

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2026: 234
Share of these events in Class II: 74%
Product records in this event: 1Median of the firm: 1
Events of the firm on the register: 4

Other events of the firm

Other FDA enforcement events of Novartis Pharmaceuticals Corporation
Initiated	Product (first record)	Type	Class	Records
22 Nov 2023	SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM H	Drug	Class I	1
16 Sep 2022	Neoral soft gelatin capsules (cyclosporine capsules, USP) Modified, 25 mg, Rx Only, 30 Soft Gelatin Capsules per carton,	Drug	Class II	1
10 May 2022	Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Containers: 12 pouches x 5 single-use containers	Drug	Class III	4

Novartis Pharmaceuticals Corporation: all 4 events

Official channels

FDA enforcement report D-0746-2026The FDA record of the first product of this event.
FDA: recalls, market withdrawals and safety alertsThe recall notices on the FDA site.
FDA MedWatchThe FDA safety reporting program for drugs and medical devices.

Follow by RSS:Food, drug and device recallsFDA Class I recalls

Cite this page

Recall Register. FDA enforcement event 99552. https://recallregister.com/fda/ii/99552/. Source: openFDA enforcement reports. Data through 28 Sep 2026.

Sources

Source: openFDA drug enforcement reports
Licence: CC0 1.0
Export date: 28 Sep 2026
Newest FDA report date on the register: 23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?: The FDA record gives this distribution: US Nationwide
How did the recall start?: The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2026 have the same class?: 74% of the 234 drug events that started in 2026 are in Class II.
How many FDA recalls does Novartis Pharmaceuticals Corporation have?: Novartis Pharmaceuticals Corporation is the recalling firm in 4 enforcement events on this register. This event is 1 of them.